Scientific
publications

Working closely with our partnered centres and universities, our researchers contribute to the progress of Life Sciences knowledge.

Allegretti M. Ruffini P. A. D’Anniballe G. Brandolini L. Bertini R. Aramini A. Antonosante A. Ferrari M. P. Mantelli F. Beccari A. Noncompetitive allosteric inhibitors of the inflammatory chemokine... CXCR1/2 inhibition enhances pancreatic islet... Safety and pharmacokinetics of escalating... Tumor-Produced Interleukin-8 Attracts... Targeting CXCR1 on breast cancer stem... Targeting the minor pocket of C5aR... CXCR1 and CXCR2 Chemokine Receptor... CXCR1/2 pathways in paclitaxel-induced... Phase II Randomized, Double-Masked... CXCR1/2 Inhibition Blocks and... Role of the chemokine receptor... Receptor binding mode and... Therapeutic inhibition of CXCR2 by... Phase Ib Pilot Study to Evaluate... Chemokine Signaling in... Blockade of the chemokine receptor... Allosteric inhibitors of chemoattractant... Topical Recombinant Human Nerve... CXCR1/2 Antagonism Is Protective... Autocrine CXCL8-dependent... Phase I Trial of Recombinant... Intravital Microscopic Evaluation of... A window-of-opportunity trial of the... The Novel C5aR Antagonist DF3016A... IL-6 and CXCL8 Mediate... Multiple Anti-Tumor Effects of Reparixin... Ladarixin, a Dual CXCR1/2 Inhibitor... CXCR1 and CXCR2 Inhibition by Ladarixin... Targeting CXCR1/2 does not improve insulin... CXCR2 Is Critical for Bacterial Control and... Emerging Role of C5 Complement Pathway in... Inhibition of osteoclast activity by complement... A randomized, placebo-controlled phase 2 study of paclitaxel... Islet allotransplantation in type 1 diabetes: Phase 2 pilot study with... CXCR2 inhibition improves islet transplantation Effect of topical recombinant human nerve growth factor... IL6 and CXCL8 mediate redundant, targetable tumor-host interactions... Phase I, randomized, double-masked, vehicle-controlled study to evaluate safety... Targeting CXCR1/2 in the first multicenter, double-blinded, randomized trial in... Tooltip

Science Direct June 2022

Ketoprofen lysine salt has a better gastrointestinal and renal tolerability than ketoprofen acid: A comparative tolerability study in the Beagle dog

Rubina Novellia, Andrea Aramini, Serena Boccella, Michela Bagnasco, Franca Cattani, Mauro Paolo Ferrari, Giovanni Goisisa, Enrico Maria Minnella, Marcello Allegretti, Virgilio Pace

Front. Bioeng. Biotechnol. June 2022

Bioengineered Human Stromal Lenticule for Recombinant Human Nerve Growth Factor Release: A Potential Biocompatible Ocular Drug Delivery System

Leonardo Mastropasqua, Mario Nubile, Giuseppina Acerra, Nicola Detta, Letizia Pelusi, Manuela Lanzini, Simone Mattioli, Manuela Santalucia, Laura Pietrangelo, Marcello Allegretti, Harminder S. Dua, Jodhbir S. Mehta, Assunta Pandolfi, Domitilla Mandatori

Frontiers in Pharmacology April 2022

Inflammation- independent antinociceptive effects of DF2755A, a CXCR1/2 selective inhibitor: a new potential therapeutic treatment for peripheral neuropathy associated to non-ulcerative interstitial cystitis/bladder pain syndrome

Laura Brandolini, Andrea Aramini, Gianluca Bianchini, Anna Ruocco, Riccardo Bertini, Rubina Novelli, Patrizia Angelico, Anna Elisa Valsecchi, Roberto Russo, Vanessa Castelli, Annamaria Cimini and Marcello Allegretti.

ACS Pharmacol. Transl. Sci. April 2022

Natural compounds inhibit SARS-CoV-2 nsp13 unwinding and ATPase enzyme activities

Angela Corona, Krzysztof Wycisk, Carmine Talarico, Candida Manelfi, Jessica Milia, Rolando Cannalire, Francesca Esposito, Philip Gribbon, Andrea Zaliani, Daniela Iaconis, Andrea R. Beccari, Vincenzo Summa, Marcin Nowotny, and Enzo Tramontano

Frontiers in Pharmacology March 2022

Tamoxifen Twists Again: On and Off-Targets in Macrophages and Infections

Chiara Sfogliarini, Giovanna Pepe, Arianna Dolce, Sara Della Torre, Maria Candida Cesta, Marcello Allegretti, Massimo Locati and Elisabetta Vegeto

International Journal of Molecular Sciences March 2022

MicroRNAs Expression in response to rhNGF in Epithelial Corneal Cells: Focus on Neurotrophin Signaling Pathway

Chiara Compagnoni, Veronica Zelli, Andrea Bianchi, Antinisca Di Marco, Roberta Capelli, Davide Vecchiotti, Laura Brandolini, Anna Maria Cimini, Francesca Zazzeroni, Marcello Allegretti, Edoardo Alesse and Alessandra Tessitore.

Frontiers in Oncology March 2022

The CXCR1/CXCR2 Inhibitor Reparixin Alters the Development of Myelofibrosis in the Gata1low Mice

Paola Verachi, Francesca Gobbo, Fabrizio Martelli, Andrea Martinelli, Giuseppe Sarli, Andrew Dunbar, Ross L. Levine, Ronald Hoffman, Maria Teresa Massucci, Laura Brandolini, Cristina Giorgio, Marcello Allegretti and Anna Rita Migliaccio on behalf of Myeloproliferative Neoplasm Research Consortium.

Frontiers in Pharmacology March 2022

Intravitreal administration of rhNGF enhances regenerative processes in a zebrafish model of retinal degeneration

Pasquale Cocchiaro, Vincenzo Di Donato, Davide Rubbini, Rodolfo Mastropasqua, Marcello Allegretti, Flavio Mantelli, Andrea Aramini and Laura Brandolini.

Orphanet Journal of Rare Diseases February 2022

Eight months follow-up of corneal nerves and sensitivity after treatment with cenegermin for neurotrophic keratopathy

Emilio Pedrotti, Erika Bonacci, Chiara Chierego, Alessandra De Gregorio, Tiziano Cozzini, Tommaso Brighenti, Grazia Caldarella, Giovanlorenzo Pastore, Adriano Fasolo & Giorgio Marchini

Orphanet Journal of Rare Diseases February 2022

Long-term clinical efficacy of topical treatment with recombinant human nerve growth factor in neurotrophic keratopathy: a novel cure for a rare degenerative corneal disease?

Alice Bruscolini, Marco Marenco, Giuseppe Maria Albanese, Alessandro Lambiase & Marta Sacchetti

Dompé farmaceutici S.p.A. Single shareholder company / Share capital € 50.000.000,00
REA MI 289519 - A registered company in Milan, Italy / Tax code and VAT number IT00791570153

Close